CCN

CCN is a biotechnology company focused on developing novel therapeutic agents that target the CCN family of proteins, which play critical roles in cell signaling, tissue repair, and disease progression. The company's primary research centers on Cell Communication Network factors (formerly known as the CCN family), specifically targeting CCN1 and CCN2 to address unmet needs in fibrosis and oncology. By modulating these matricellular proteins, CCN aims to inhibit pathological scarring and tumor growth while promoting healthy tissue regeneration. The company is currently advancing several pre-clinical programs aimed at treating chronic conditions such as diabetic nephropathy and various solid tumors.